| Cat. No. |
Product Name |
Information |
| PC-62007 |
LSN 3213128
AICARFT inhibitor
|
LSN 3213128 is a novel potent, selective and orally-bioavailable antifolate with potent and specific inhibitory activity for AICARFT. |
| PC-60506 |
Arfolitixorin
|
Arfolitixorin is a novel antifolate modulator compound, is a substrate for methylenetetrahydrofolate reductase to generate 5-methyltetrahydrofolate |
| PC-70211 |
LY345899
MTHFD1/2 inhibitor
|
LY345899 (LY 345899) is a novel potent, cytoplasmic and mitochondrial methylenetetrahydrofolate dehydrogenase MTHFD1 and MTHFD2 inhibitor with IC50 of 96 nM and 663 nM, respectively. |
| PC-42556 |
Trimetrexate
DHFR inhibitor
|
Trimetrexate (CI-898, NSC249008) is a quinazoline derivative and antifolate agent that fuctions as a dihydrofolate reductase (DHFR) inhibitor. |
| PC-26410 |
Methotrexate
Antifolate
|
Methotrexate is antifolate agent and dihydrofolate reductase (DHFR) inhibitor. |
| PC-26409 |
Lometrexol
GARFT inhibitor, SHMT inhibitor
|
Lometrexol (DDATHF) is an antipurine antifolate and inhibitor of glycinamide ribonucleotide formyltransferase (GARFT), also inhibits serine hydroxymethyltransferase (SHMT) with ITC KD of 2 uM. |
| PC-26408 |
Nolatrexed
Antifolate
|
Nolatrexed (AG337) is an orally active antifolate agent and thymidylate synthase (TS) inhibitor. |
| PC-26406 |
MTHFD2 inhibitor 31
MTHFD2 inhibitor
|
MTHFD2 inhibitor 31 is a potent, highly selective MTHFD2 inhibitor with IC50 of 38 nM, >180-fold selective over MTHFD1 (IC50=7440 nM). |
| PC-26405 |
MTHFD1/2 inhibitor 34
MTHFD1/2 inhibitor
|
MTHFD1/2 inhibitor 34 is a potent, dual MTHFD1/2 inhibitor with IC50 of 0.26 uM and 0.031 uM for MTHFD1 and MTHFD2 respectively. |
| PC-23433 |
UCP1162
DHFR inhibitor
|
UCP1162 is a potent propargyl-linked inhibitor of dihydrofolate reductase (DHFR) with IC50 of 21.8 nM for inhibition of DHFR to catalyze the NADPH-dependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). |
| PC-45348 |
Calcium N5-methyltetrahydrofolate
|
The calcium salt of levomefolic acid that has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers. . |
| PC-42590 |
Pralatrexate
|
An antifolate that fuctions as a dihydrofolate reductase inhibitor for treatment of several malignancies.. |
